Biologics Beyond Boundaries: Innovative Use of Biologics in Dermatology.
Several biologic agents have been approved for use in dermatology and other disciplines of medicine. However, based on the mechanism of action and a track record of the response, these agents are being increasingly used for off-label purposes to garner control of more remote and difficult disease pr...
| Publicado en: | Indian Journal of Dermatology Vol. 66; no. 3; pp. 314 - 318 |
|---|---|
| Autores principales: | , , , , |
| Formato: | case study pictorial Journal Article |
| Publicado: |
Wolters Kluwer India Pvt Ltd
May/Jun2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151527232&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 151527232 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00195154 259H jtl: Indian Journal of Dermatology issn: 00195154 maglogo: N pubinfo: dt: May/Jun2021 vid: 66 iid: 3 pid: 16919 pub: Wolters Kluwer India Pvt Ltd artinfo: ui: 151527232 151527232 151527232 10.4103/ijd.IJD_128_20 151527232 ppf: 314 ppct: 4 formats: tig: atl: Biologics Beyond Boundaries: Innovative Use of Biologics in Dermatology. aug: au: De, Abhishek Chowdhury, Barnali Khemka, Monika Sarda, Aarti Das, Sudip affil: From the Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal sug: subj: Biological Products Therapeutic Use Pemphigoid, Bullous Drug Therapy Antibodies, Monoclonal Therapeutic Use Hansen's Disease Drug Therapy Tenosynovitis Drug Therapy Erythema Nodosum Drug Therapy Infliximab Therapeutic Use Pyoderma Gangrenosum Drug Therapy Dermatologic Agents Therapeutic Use Drug Efficacy Aged Female Adult Male Pemphigoid, Bullous Hansen's Disease Diagnosis Tenosynovitis Diagnosis Erythema Nodosum Diagnosis Biopsy, Needle Pyoderma Gangrenosum Diagnosis Leprostatic Agents Therapeutic Use Steroids Therapeutic Use Biopsy Fluoroimmunoassay Aged: 65+ years Adult: 19-44 years Female Male ab: Several biologic agents have been approved for use in dermatology and other disciplines of medicine. However, based on the mechanism of action and a track record of the response, these agents are being increasingly used for off-label purposes to garner control of more remote and difficult disease processes. Herein, we present three difficult to treat patients where innovative uses of biologics beyond their approved indications have yielded good responses. Our first patient was a case of bullous pemphigoid, who showed excellent response to omalizumab. The second case was a patient of lepromatous leprosy with tenosynovitis and erythema nodosum leprosum, who was treated effectively with infliximab. Our third case was a treatment-resistant pyoderma gangrenosum, where infliximab showed a very good response. In the present study, we report the cases to highlight the usefulness of biologics that can expand much beyond the routine FDA approved indications. pubtype: Academic Journal doctype: case study pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|